Alzheimer's Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
2 min read
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
The Food and Drug Administration's decision on Monday to approve a new Alzheimer's medication over the fierce objections of its scientific advisers sets into motion one of the most controversial drug introductions in years.

For its manufacturer, Biogen, the new drug is poised to be a blockbuster. For just about everyone else, it is likely to further inflate high…
Rebecca Robbins, Pam Belluck
Read full article